Table 3.
Major inhibitors of CypA and potential therapeutic strategies.
Inhibitors | Mechanism | Therapeutic Potential | Targeted Cancer | References |
---|---|---|---|---|
CsA | PPIase activity | Interference of CypA and CD147 binding, Induction of apoptosis | Breast cancer, Lung adenocarcinoma | 113,120 |
Debio-025 (Alisporivir) | Crk signaling | Non-immunosuppressive analogue of CsA, Potent antitumor and antimetastatic activity, Enhancing of tumor immunogenicity and anti-PD-1 therapy | Breast cancer, Hepatitis C-hepatocellular carcinoma | 121 |
Sanglifehrin A | PPIase activity | Binding to CypA with higher affinity than CsA | Glioblastoma multiforme | 66,122 |
SCY-635, NIM811 | NS5A | Non-immunosuppressive activity, Inhibition of hepatocarcinogenesis | Hepatitis C-hepatocellular carcinoma | 22 |
NV651 | PPIase activity | Non-immunosuppressive activity, inbibition of cell proliferation and tumor growth in vivo | Hepatocellular carcinoma | 123 |
23-demethyl 8, 13-deoxynargenicin (C9) | MAPK signaling | Inhibition of proliferation, migration, invasion and angiogenesis | Gastric cancer | 124 |
Melittin | MMP-9 | Inhibition of metastasis | Breast cancer | 125 |
RNA interference | PPIase activity | Inhibition of tumor growth, Enhancing of radiosensitivity | Lung adenocarcinoma | 116 |
NF-κB signaling | Inhibition of glioblastoma growth | Glioblastoma | 126 | |
Blocking interaction | CypA/CD147 interaction | Inhibition of tumor growth, metastasis, invasion | Hepatocellular carcinoma, breast cancer | 100 |